Back to News
Market Impact: 0.25
JNJ Announces CHMP's Recommendation For Approval Of TECVAYLI
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Johnson & Johnson announced that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended an indication extension for TECVAYLI to treat adult patients with relapsed/refractory multiple myeloma. The positive regulatory recommendation could expand TECVAYLI's eligible patient population in Europe, although final European Commission approval is still pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
JNJ0.55
More News
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- California’s Bay Area debates data centres ahead of US midterm elections
- ‘Fastest entertainment property in history’: GTA VI arrives to test a thin November box office
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Going hungry’: Garment workers in Bangladesh say wages barely cover needs